It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Bladder cancer (BC) is heterogeneous and expresses various cell surface targets. Photoimmunotherapy (PIT) involves monoclonal antibodies (MAbs) conjugated to a photoabsorber (PA), IR Dye 700Dx, and then activated by near infra-red light (NIR) to specifically target tumors. We have demonstrated that tumors expressing EGFR can be targeted with PIT. However, PIT may be less effective when a tumor lacks “overwhelming” expression of a single target such as EGFR. We present a combinatorial PIT approach for targeting BC expressing EGFR and HER2, using PA- labeled panitumumab (pan) and trastuzumab (tra), respectively. Human BC tissues and cell lines were analyzed for EGFR and HER2 expression. Efficacy of PA-labeled MAbs singly and in combination was analyzed. About 45% of BC tissues stain for both EGFR and HER2. In vitro, the combination of pan IR700 and tra IR700 with NIR was more efficacious than either agent alone. Tumor xenografts treated with combination PIT showed significant tumor growth retardation. Combination PIT is a promising approach for treating BC with low/moderate expression of surface receptors. In addition, given the molecular heterogeneity of bladder cancer, targeting more than one surface receptor may allow for more effective cell death across different bladder tumors.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Center for Cancer Research, National Cancer Institute, Urologic Oncology Branch, Bethesda, USA (GRID:grid.417768.b) (ISNI:0000 0004 0483 9129); Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, USA (GRID:grid.16753.36) (ISNI:0000 0001 2299 3507)
2 Center for Cancer Research, National Cancer Institute, Urologic Oncology Branch, Bethesda, USA (GRID:grid.417768.b) (ISNI:0000 0004 0483 9129)
3 Office of the Director, National Institutes of Health, Diagnostic and Research Services Branch, Bethesda, USA (GRID:grid.453125.4)
4 Leidos Biomedical Research, Inc. Frederick National Laboratory for Cancer Research, Pathology Section, Pathology/Histotechnology Laboratory, Frederick, USA (GRID:grid.418021.e) (ISNI:0000 0004 0535 8394)
5 Center for Cancer Research, National Cancer Institute, Molecular Imaging Program, Bethesda, USA (GRID:grid.417768.b) (ISNI:0000 0004 0483 9129)